Oxamniquine is an alternative treatment to praziquantel for Schistosoma mansoni infections. It is effective against both mature and immature stages of S. mansoni by causing contraction and paralysis of the worms. It has been used for mass treatment and can be effective against praziquantel-resistant strains. It is absorbed orally but is not effective against S. haematobium or S. japonicum.
Oxamniquine is an alternative treatment to praziquantel for Schistosoma mansoni infections. It is effective against both mature and immature stages of S. mansoni by causing contraction and paralysis of the worms. It has been used for mass treatment and can be effective against praziquantel-resistant strains. It is absorbed orally but is not effective against S. haematobium or S. japonicum.
Oxamniquine is an alternative treatment to praziquantel for Schistosoma mansoni infections. It is effective against both mature and immature stages of S. mansoni by causing contraction and paralysis of the worms. It has been used for mass treatment and can be effective against praziquantel-resistant strains. It is absorbed orally but is not effective against S. haematobium or S. japonicum.
Oxamniquine is an alternative treatment to praziquantel for Schistosoma mansoni infections. It is effective against both mature and immature stages of S. mansoni by causing contraction and paralysis of the worms. It has been used for mass treatment and can be effective against praziquantel-resistant strains. It is absorbed orally but is not effective against S. haematobium or S. japonicum.
Download as PPTX, PDF, TXT or read online from Scribd
Download as pptx, pdf, or txt
You are on page 1of 7
OXAMNIQUINE
• Oxamniquine is an alternative to praziquantel for the treatment of S
mansoni infections. • It has also been used extensively for mass treatment. • It is not effective against S haematobium or S japonicum. Anthelmintic Actions • Oxamniquine is active against both mature and immature stages of S mansoni but does not appear to be cercaricidal. • The mechanism of action is unknown. • Contraction and paralysis of the worms results in detachment from terminal venules in the mesentery and transit to the liver. • Oxamniquine has been effective in instances of praziquantel resistance. Clinical Uses • safe and effective in all stages of S mansoni disease, including advanced hepatosplenomegaly. • results disappearance of acute symptoms and clearance of the infection in treatment of acute (Katayama) syndrome. • used in combination with metrifonate for mixed schistosome infections • Optimal dosage schedules vary for different regions of the world. • less effective in children • better-tolerated with food. Pharmacokinetics • Oxamniquine is readily absorbed orally. • Its plasma half-life is about 2.5 hours. • The drug is extensively metabolized to inactive metabolites and excreted in the urine up to 75% in the first 24 hours. • Intersubject variations in serum concentration have been noted, which may explain some treatment failures. Adverse Reactions • Central nervous system symptoms (dizziness, headache, drowsiness) are most common. • Nausea and vomiting, diarrhea, colic, pruritus, and urticaria also occur Infrequently • May cause low-grade fever, an orange to red discoloration of the urine, proteinuria, microscopic hematuria, and a transient decrease in leukocytes. • Seizures have been reported rarely. Contraindications • Since the drug makes many patients dizzy or drowsy, it should be used with caution in patients whose work or activity requires mental alertness. • should be used with caution in those with a history of epilepsy. • contraindicated in pregnancy Doxycycline • tetracyclic antibiotic agent • has recently been shown to have significant macrofilaricidal activity against W bancrofti • has activity against onchocerciasis. • Doxycycline with ivermectin has complementary therapy for the control of onchocerciasis. • Can reduce the transmission and occurrence of onchocercal eye disease.